Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia, results from two clinical trials

Patients with acute myeloid leukemia (AML), who are refractory to induction therapy or experience relapse after a first complete remission (CR), have an unfavorable prognosis.[1][1] Epigenetic dysregulation is frequent in AML. In preclinical studies, the pan-deacetylase inhibitor (DACi) panobinostat